iX Biopharma: Wafermine plans ‘not dependent’ on Nevada partner Orion, which lacks state license
It says it is assessing several manufacturing pathways to fulfill its US DoD contract to supply the drug
Specialty pharmaceutical company iX Biopharma says its plans to manufacture the drug Wafermine for the US military are not dependent on its proposed joint venture partner Orion Specialty Labs. The latter company, which has yet to secure a required operating license in Nevada, has been facing scrutiny over its ability to manufacture drugs for iX Biopharma's US operations. iX Biopharma's chief commercial officer, Eva Tan, clarified that the US$41 million contract with the US Department of Defense (DoD) is separate from the planned joint venture with Orion.
The company seeks to fulfill Wafermine orders under the DoD contract using infrastructure that was relocated from its Australian manufacturing facility to Orion's Nevada site. Tan also noted that the joint venture agreement is still in the advanced stage of negotiation and that the company expects the Nevada licensing to follow the finalization of the joint venture and installation of its manufacturing equipment.
Written by urgent.news from The Business Times - Companies & Markets's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
